Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoglobulin E plays an immunoregulatory role in lupus.
Dema B, Charles N, Pellefigues C, Ricks TK, Suzuki R, Jiang C, Scheffel J, Hasni S, Hoffman V, Jablonski M, Sacré K, Gobert D, Papo T, Daugas E, Crampton S, Bolland S, Rivera J. Dema B, et al. Among authors: ricks tk. J Exp Med. 2014 Oct 20;211(11):2159-68. doi: 10.1084/jem.20140066. Epub 2014 Sep 29. J Exp Med. 2014. PMID: 25267791 Free PMC article.
Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis.
Dema B, Pellefigues C, Hasni S, Gault N, Jiang C, Ricks TK, Bonelli MM, Scheffel J, Sacré K, Jablonski M, Gobert D, Papo T, Daugas E, Illei G, Charles N, Rivera J. Dema B, et al. Among authors: ricks tk. PLoS One. 2014 Feb 28;9(2):e90424. doi: 10.1371/journal.pone.0090424. eCollection 2014. PLoS One. 2014. PMID: 24587356 Free PMC article.
FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.
Agrawal S, Lee C, Pierce WF, Everhart E, King-Ducre A, Royce M, Osgood CL, Amiri-Kordestani L, Chiu HJ, Ricks TK, Pan L, Fourie Zirkelbach J, Charlab R, Pacanowski M, Kim T, Pazdur R, Kluetz PG, Gao JJ. Agrawal S, et al. Among authors: ricks tk. Clin Cancer Res. 2024 Oct 8. doi: 10.1158/1078-0432.CCR-24-1708. Online ahead of print. Clin Cancer Res. 2024. PMID: 39377782
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.
Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks TK, Schaefer T, Avasarala S, Reyes Turcu F, Pathak A, Kalavar S, Bhatnagar V, Collazo J, Rahman NA, Mixter B, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L. Dilawari A, et al. Among authors: ricks tk. J Clin Oncol. 2024 Aug 19:JCO2400427. doi: 10.1200/JCO.24.00427. Online ahead of print. J Clin Oncol. 2024. PMID: 39159418
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
Heiss BL, Chang E, Gao X, Truong T, Brave MH, Bloomquist E, Shah A, Hamed S, Kraft J, Chiu HJ, Ricks TK, Tilley A, Pierce WF, Tang L, Abukhdeir A, Kalavar S, Philip R, Tang S, Pazdur R, Amiri-Kordestani L, Kluetz PG, Suzman DL. Heiss BL, et al. Among authors: ricks tk. J Clin Oncol. 2024 May 20;42(15):1851-1860. doi: 10.1200/JCO.23.02182. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452327 Clinical Trial.
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.
Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, Biel N, Ricks TK, Fu W, Hamed S, Li F, Sun JJ, Fan J, Schuck R, Grimstein M, Tang L, Kalavar S, Abukhdeir A, Pathak A, Ghosh S, Bulatao I, Tilley A, Pierce WF, Mixter BD, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L. Shah M, et al. Among authors: ricks tk. J Clin Oncol. 2024 Apr 1;42(10):1193-1201. doi: 10.1200/JCO.23.02112. Epub 2024 Feb 21. J Clin Oncol. 2024. PMID: 38381994 Clinical Trial.
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Gao JJ, Osgood CL, Feng Z, Bloomquist EW, Tang S, Chang CJG, Ricks TK, Hou SC, Pierce WF, Rivera DR, Pazdur R, Kluetz PG, Amiri-Kordestani L. Gao JJ, et al. Among authors: ricks tk. Clin Cancer Res. 2023 Dec 15;29(24):5008-5011. doi: 10.1158/1078-0432.CCR-23-1133. Clin Cancer Res. 2023. PMID: 37594723 Free PMC article.
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L. Dilawari A, et al. Among authors: ricks tk. Clin Cancer Res. 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. Clin Cancer Res. 2023. PMID: 37212825 Free PMC article.
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, Chen W, Ricks TK, Niu G, Fotenos A, Wang M, Chiang K, Pierce WF, Suzman DL, Tang S, Pazdur R, Amiri-Kordestani L, Ibrahim A, Kluetz PG. Fallah J, et al. Among authors: ricks tk. Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875. Clin Cancer Res. 2023. PMID: 36469000 Free PMC article. Clinical Trial.
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA. Fallah J, et al. Among authors: ricks tk. Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054. Clin Cancer Res. 2022. PMID: 35727604 Free PMC article.
27 results